30 results
The primary objective of the ERY-PAO study is to investigate the pharmacokinetics of acetylsalicylic acid (ASA) and omeprazole in morbidly obese subjects before and after RYGB surgery and to compare these data to study if there are differences in…
To determine whether fibrinogen concentrate infusion reduces perioperative blood loss and transfusion in patient experiencing clinically relevant microvascular bleeding during elective complex cardiac surgery and to determine whether its use is safe…
The study will assess the hypothesis that the combination warfarin & clopidogrel 75 mg/day is superior to triple therapy (warfarin + clopidogrel 75mg/day + aspirin 80mg/day) with respect to bleeding complications while equally safe with…
Primary Objectives:1. To compare the magnitude of baseline (or intrinsic) platelet reactivity between T2DM patients and healthy volunteers using multiple platelet function assays 2. To compare the magnitude of baseline (or intrinsic) platelet…
-To assess the feasibility of relatively frequent measurements of whole blood platelet aggregometry using collagen as inducer;-To assess the effects of ASA treatment on collagen-induced platelet aggregation (primary endpoint);-To investigate the…
The purpose of this study is to answer the following question: Leads a primary coagulation corrected with a single dose of fibrinogen concentrate after ascending aorta-arc reconstruction to a decrease in the number of allogenic blood transfusions,…
To determine the best dose escalation scheme of dipyridamole added to acetylsalicylic acid, based on the side-effect headache, in patients starting secondary preventive therapy for stroke
To demonstrate non-inferiority of continuation of platelet inhibiting drugs in eyelid surgery regarding the risk of haemorrhagic complications.
To measure the pharmacodynamic interaction between naproxen + acetylsalicylic acid as compared to the placebo + acetylsalicylic interaction. Also the pharmacodynamic interaction between acetylsalicylic acid and other in The Netherlands often used…
The main objective of this study is to determine the role of glycaemic control in diabetes mellitus in the occurrence of acetylsalicylic acid resistance, the secondary objective is to determine the effect of increased dosing on acetylsalicylic acid…
To investigate whether COX-2 inhibition enhances platelet aggregation by suppression of prostacyclin formation without suppressing thromboxane formation
To study whether ticagrelor, added to acetylsalicylic acid, modulates the inflammatory response to the administration of lipopolysaccharide (LPS) in humans in vivo.
Primary objective:To determine whether endotoxin tolerance can be prevented by acetylsalicylic acid prophylaxis or can be reversed by acetylsalicylic acid treatment, expressed as an augmentation of pro-inflammatory cytokine levels during the second…
Despite continuous improvements in the medical management of pediatric patients with CHD, the risk of thrombotic events remains an important complication for pediatric patients following the Fontan procedure.The National Heart, Lung and Blood…
To determine the prevalence and severity of aspirin-related allergic reactions in SM patients.
The primary objective is to compare a 12-month antithrombotic regimen of edoxaban in combination with clopidogrel or another P2Y12 antagonist against a regimen of a vitamin K antagonist (VKA) in combination with clopidogrel or another P2Y12…
To assess the effectiveness of low dose aspirin compared with placebo in prevention of recurrent spontaneous preterm birth.
To study the effectiveness of low-dose rivaroxaban with aspirin in improving endothelial function in patients with symptomatic or stable PAD.
Our main goal is to establish whether there is difference in the effect between the use of aspirin, dualtherapy aspirin/clopidogrel, or ticagrelor on the occurrence of atherothrombotic events in patients following lower extremity peripheral…
Primary Objective: to obtain reliable estimates of the rates of vascular death and non-fatal stroke in patients with atrial fibrillation and a recent anticoagulation-associated ICH who are treated with apixaban versus those who are treated with APDs…